Please assess the completion status of the following clinical trial:

Trial Title: ALK21-003: Study of Medisorb® Naltrexone (VIVITROL®) in Alcohol-Dependent Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Primary Inclusion Criteria:~* Diagnosis of alcohol dependence based on Diagnostic and Statistical Manual of Mental Disorders, 4th Ed. (DSM-IV) criteria~* Male or non-pregnant, non-lactating female~* Able to provide TimeLine Follow-Back (TLFB) alcohol consumption information for 90-day period before detoxification and/or screening~* At least 2 episodes of heavy alcohol drinking per week during the 30 days before detoxification and/or screening~* Negative urine toxicological screen for opiates on day of randomization~* Noncustodial, stable residence and phone plus 1 contact with verifiable address and phone~Primary Exclusion Criteria:~* Evidence of hepatic failure including: ascites, prolonged prothrombin time (PT) (international normalized ratio \[INR\] ≥1.7), bilirubin \>10% above upper limit of normal (ULN) and/or esophageal variceal disease~* Active hepatitis and/or aspartate aminotransferase (AST) or alanine aminotransferase (ALT) higher than 3xULN~* History of pancreatitis~* Major depression with suicidal ideation, psychosis, bipolar disorder, or psychiatric disorders that would compromise subject's ability to complete the study~* Current dependence (within past year) per DSM-IV criteria to benzodiazepines, opioids or cocaine~* Use of benzodiazepines and/or Ambien® (zolpidem tartrate) within 7 days prior to first dose of study medication~* Greater than 7 days inpatient treatment for substance use disorders within 30 days of randomization~* Use of any opioids and/or methadone within 14 days of screening, or likely requiring opioid therapy during study period~* Use of oral naltrexone or disulfiram within 14 days of screening~* Known intolerance and/or hypersensitivity to naltrexone, carboxymethylcellulose, or polylactide-co-glycolide (PLG)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Medisorb naltrexone 190 mg (Type: EXPERIMENTAL): None
- Medisorb naltrexone 380 mg (Type: EXPERIMENTAL): None
- Placebo for Medisorb naltrexone 190 mg (Type: PLACEBO_COMPARATOR): None
- Placebo for Medisorb naltrexone 380 mg (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).